In this study, we aimed to evaluate the effectiveness of the implementation effort involving the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin for individuals with heart failure and reduced ejection fraction when applying the systematic approach in an outpatient heart failure clinic. Here, SLC5A2 is linked to heart failure.